Cargando…

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Todd, Jamie L., Vinisko, Richard, Liu, Yi, Neely, Megan L., Overton, Robert, Flaherty, Kevin R., Noth, Imre, Newby, L. Kristin, Lasky, Joseph A., Olman, Mitchell A., Hesslinger, Christian, Leonard, Thomas B., Palmer, Scott M., Belperio, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071646/
https://www.ncbi.nlm.nih.gov/pubmed/32171287
http://dx.doi.org/10.1186/s12890-020-1103-4
_version_ 1783506249591029760
author Todd, Jamie L.
Vinisko, Richard
Liu, Yi
Neely, Megan L.
Overton, Robert
Flaherty, Kevin R.
Noth, Imre
Newby, L. Kristin
Lasky, Joseph A.
Olman, Mitchell A.
Hesslinger, Christian
Leonard, Thomas B.
Palmer, Scott M.
Belperio, John A.
author_facet Todd, Jamie L.
Vinisko, Richard
Liu, Yi
Neely, Megan L.
Overton, Robert
Flaherty, Kevin R.
Noth, Imre
Newby, L. Kristin
Lasky, Joseph A.
Olman, Mitchell A.
Hesslinger, Christian
Leonard, Thomas B.
Palmer, Scott M.
Belperio, John A.
author_sort Todd, Jamie L.
collection PubMed
description BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing patients with IPF from controls and to explore associations between MMPs/TIMPs and measures of disease severity in patients with IPF. METHODS: The IPF cohort (n = 300) came from the IPF-PRO Registry, an observational multicenter registry of patients with IPF that was diagnosed or confirmed at the enrolling center in the past 6 months. Controls (n = 100) without known lung disease came from a population-based registry. Generalized linear models were used to compare circulating concentrations of MMPs 1, 2, 3, 7, 8, 9, 12, and 13 and TIMPs 1, 2, and 4 between patients with IPF and controls, and to investigate associations between circulating levels of these proteins and measures of IPF severity. Multivariable models were fit to identify the MMP/TIMPs that best distinguished patients with IPF from controls. RESULTS: All the MMP/TIMPs analyzed were present at significantly higher levels in patients with IPF compared with controls except for TIMP2. Multivariable analyses selected MMP8, MMP9 and TIMP1 as top candidates for distinguishing patients with IPF from controls. Higher concentrations of MMP7, MMP12, MMP13 and TIMP4 were significantly associated with lower diffusion capacity of the lung for carbon monoxide (DL(CO)) % predicted and higher composite physiologic index (worse disease). MMP9 was associated with the composite physiologic index. No MMP/TIMPs were associated with forced vital capacity % predicted. CONCLUSIONS: Circulating MMPs and TIMPs were broadly elevated among patients with IPF. Select MMP/TIMPs strongly associated with measures of disease severity. Our results identify potential MMP/TIMP targets for further development as disease-related biomarkers.
format Online
Article
Text
id pubmed-7071646
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70716462020-03-18 Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort Todd, Jamie L. Vinisko, Richard Liu, Yi Neely, Megan L. Overton, Robert Flaherty, Kevin R. Noth, Imre Newby, L. Kristin Lasky, Joseph A. Olman, Mitchell A. Hesslinger, Christian Leonard, Thomas B. Palmer, Scott M. Belperio, John A. BMC Pulm Med Research Article BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) play important roles in the turnover of extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study aimed to determine the utility of circulating MMPs and TIMPs in distinguishing patients with IPF from controls and to explore associations between MMPs/TIMPs and measures of disease severity in patients with IPF. METHODS: The IPF cohort (n = 300) came from the IPF-PRO Registry, an observational multicenter registry of patients with IPF that was diagnosed or confirmed at the enrolling center in the past 6 months. Controls (n = 100) without known lung disease came from a population-based registry. Generalized linear models were used to compare circulating concentrations of MMPs 1, 2, 3, 7, 8, 9, 12, and 13 and TIMPs 1, 2, and 4 between patients with IPF and controls, and to investigate associations between circulating levels of these proteins and measures of IPF severity. Multivariable models were fit to identify the MMP/TIMPs that best distinguished patients with IPF from controls. RESULTS: All the MMP/TIMPs analyzed were present at significantly higher levels in patients with IPF compared with controls except for TIMP2. Multivariable analyses selected MMP8, MMP9 and TIMP1 as top candidates for distinguishing patients with IPF from controls. Higher concentrations of MMP7, MMP12, MMP13 and TIMP4 were significantly associated with lower diffusion capacity of the lung for carbon monoxide (DL(CO)) % predicted and higher composite physiologic index (worse disease). MMP9 was associated with the composite physiologic index. No MMP/TIMPs were associated with forced vital capacity % predicted. CONCLUSIONS: Circulating MMPs and TIMPs were broadly elevated among patients with IPF. Select MMP/TIMPs strongly associated with measures of disease severity. Our results identify potential MMP/TIMP targets for further development as disease-related biomarkers. BioMed Central 2020-03-14 /pmc/articles/PMC7071646/ /pubmed/32171287 http://dx.doi.org/10.1186/s12890-020-1103-4 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Todd, Jamie L.
Vinisko, Richard
Liu, Yi
Neely, Megan L.
Overton, Robert
Flaherty, Kevin R.
Noth, Imre
Newby, L. Kristin
Lasky, Joseph A.
Olman, Mitchell A.
Hesslinger, Christian
Leonard, Thomas B.
Palmer, Scott M.
Belperio, John A.
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title_full Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title_fullStr Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title_full_unstemmed Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title_short Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
title_sort circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter ipf-pro registry cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071646/
https://www.ncbi.nlm.nih.gov/pubmed/32171287
http://dx.doi.org/10.1186/s12890-020-1103-4
work_keys_str_mv AT toddjamiel circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT viniskorichard circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT liuyi circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT neelymeganl circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT overtonrobert circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT flahertykevinr circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT nothimre circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT newbylkristin circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT laskyjosepha circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT olmanmitchella circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT hesslingerchristian circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT leonardthomasb circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT palmerscottm circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT belperiojohna circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort
AT circulatingmatrixmetalloproteinasesandtissuemetalloproteinaseinhibitorsinpatientswithidiopathicpulmonaryfibrosisinthemulticenteripfproregistrycohort